Peptides / Glutathione / United Kingdom

Glutathione in the United Kingdom

Legal status, what it is, and the listed suppliers in the United Kingdom that list it.

Legal status in the United Kingdom

Not an approved medicine.

As understood at 2026-09-22. Verify with the MHRA.

What Glutathione is

Glutathione is a tripeptide, three amino acids joined together (glutamate, cysteine and glycine), made by nearly every cell in the body and the most abundant antioxidant inside cells. Unlike most substances on this site it occurs naturally in everyone, and the question its research asks is not what it does but whether taking more of it changes anything.

Full Glutathione page: targets and research →

Clinical Research

Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Richie JP, Nichenametla S, Neidig W, et al. (2015). European Journal of Nutrition. human 54 non-smoking adults, randomised double-blind placebo-controlled, 6 months
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser RA, Lyons KE, McClain T, et al. (2009). Movement Disorders. human 21 people with Parkinson's disease whose symptoms were not well controlled on existing medication; randomised, double-blind, placebo-controlled, 4 weeks
Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial
Kumar P, Liu C, Suliburk J, et al. (2023). The Journals of Gerontology: Series A. human 24 older adults randomised to GlyNAC or placebo for 16 weeks, plus 12 young adults given GlyNAC for 2 weeks as a comparison
The effects of the oral supplementation of L-Cystine associated with reduced L-Glutathione-GSH on human skin pigmentation: a randomized, double-blinded, benchmark- and placebo-controlled clinical trial
Duperray J, Sergheraert R, Chalothorn K, et al. (2022). Journal of Cosmetic Dermatology. human 124 Asian female participants in four equal groups; randomised, double-blind, benchmark- and placebo-controlled, 12 weeks